Page 606 - Clinical Immunology_ Principles and Practice ( PDFDrive )

584 ParT FIvE Allergic Diseases

8. Solelhac G, Charpin D. Management of allergic rhinitis. F1000Prime Rep 29. Davoine F, Lacy P. Eosinophil cytokines, chemokines, and growth factors:
2014;6:94. emerging roles in immunity. Front Immunol 2014;5:570.
9. Porter PC, Lim DJ, Maskatia ZK, et al. Airway surface mycosis in chronic 30. Zhang X, Kohl J. A complex role for complement in allergic asthma. Exp
TH2-associated airway disease. J Allergy Clin Immunol 2014;134:325–31. Rev Clin Immunol 2010;6:269–77.
10. Rains BM 3rd, Mineck CW. Treatment of allergic fungal sinusitis with 31. Kanaoka Y, Boyce JA. Cysteinyl leukotrienes and their receptors; emerging
high-dose itraconazole. Am J Rhinol 2003;17:1–8. concepts. Allergy Asthma Immunol Res 2014;6:288–95.
11. Corry DB, Irvin CG. Promise and pitfalls in animal-based asthma 32. Bonnans C, Levy BD. Lipid mediators as agonists for the resolution of
research: building a better mousetrap. Immunol Res 2006;35:279–94. acute lung inflammation and injury. Am J Respir Cell Mol Biol
12. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic 2007;36:201–5.
asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. 33. Porter P, Polikepahad S, Qian Y, et al. Respiratory tract allergic disease
Lancet 2012;380:651–9. and atopy: experimental evidence for a fungal infectious etiology. Med
13. Iyer VN, Lim KG. Bronchial thermoplasty: where there is smoke, there is Mycol 2011;49:S158–63.
fire. Allergy Asthma Proc 2015;36:251–5. 34. Newcomb DC, Peebles RS Jr. Bugs and asthma: a different disease? Proc
14. Lee JH, Park HK, Heo J, et al. Drug Rash with Eosinophilia and Systemic Am Thorac Soc 2009;6:266–71.
Symptoms (DRESS) syndrome induced by celecoxib and anti-tuberculosis 35. Dozor AJ. The role of oxidative stress in the pathogenesis and treatment
drugs. J Korean Med Sci 2008;23:521–5. of asthma. Ann NY Acad Sci 2010;1203:133–7.
15. Knutsen AP, Bush RK, Demain JG, et al. Fungi and allergic lower 36. Porter PC, Yang T, Luong A, et al. Proteinases as molecular adjuvants in
respiratory tract diseases. J Allergy Clin Immunol 2012;129:280–91, quiz allergic airway disease. Biochim Biophys Acta 2011;11:1059–65.
292–3. 37. Millien VO, Lu W, Mak G, et al. Airway fibrinogenolysis and the initiation
16. Swartz J, Stoller JK. Acute eosinophilic pneumonia complicating of allergic inflammation. Ann Am Thorac Soc 2014;11:S277–83.
Coccidioides immitis pneumonia: a case report and literature review. 38. Richerson HB, Bernstein IL, Fink JN, et al. Guidelines for the clinical
Respiration 2009;77:102–6. evaluation of hypersensitivity pneumonitis. Report of the Subcommittee
17. Uchiyama H, Suda T, Nakamura Y, et al. Alterations in smoking habits are on Hypersensitivity Pneumonitis. J Allergy Clin Immunol
associated with acute eosinophilic pneumonia. Chest 2008;133:1174–80. 1989;84:839–44.
18. Yoshimi M, Nannya Y, Watanabe T, et al. Acute eosinophilic pneumonia is 39. Hobbs B, Parker M, Chen H, et al. Exome array analysis identifies a
a non-infectious lung complication after allogeneic hematopoietic stem common variant in IL27 associated with chronic obstructive pulmonary
cell transplantation. Int J Hematol 2009;89:244–8. disease. Am J Respir Crit Care Med 2016;194:48–57.
19. Rose DM, Hrncir DE. Primary eosinophilic lung diseases. Allergy Asthma 40. Vestbo J. COPD: definition and phenotypes. Clin Chest Med 2014;
Proc 2013;34:19–25. 35:1–6.
20. Curtis C, Ogbogu P. Hypereosinophilic syndrome. Clin Rev Allergy 41. You R, Lu W, Shan M, et al. Nanoparticulate carbon black in cigarette
Immunol 2016;50:240–51. smoke induces DNA cleavage and Th17-mediated emphysema. elife
21. Gioffredi A, Maritati F, Oliva E, et al. Eosinophilic granulomatosis with 2015;4:e09623.
polyangiitis: an overview. Front Immunol 2014;5:549. 42. Kheradmand F, Shan M, Xu C, et al. Autoimmunity in chronic
22. Gell PGH, Coombs RRA. Clinical aspects of immunology. Oxford, obstructive pulmonary disease: clinical and experimental evidence.
England: Blackwell; 1963. [Review]. Exp Rev Clin Immunol 2012;8:285–92.
23. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo 43. Hammad H, Lambrecht BN. Barrier epithelial cells and the control of
veritas. J Clin Investig 2012;122:787–95. type 2 immunity. Immunity 2015;43:29–40.
24. Fireman P. Understanding asthma pathophysiology. Allergy Asthma Proc 44. Shan M, You R, Yuan X, et al. Agonistic induction of PPAR reverses
2003;24:79–83. cigarette smoke-induced emphysema. J Clin Invest 2014;124:
25. Zhu J. T helper 2 (Th2) cell differentiation, type 2 innate lymphoid cell 1371–81.
(ILC2) development and regulation of interleukin-4 (IL-4) and IL-13 45. Mandal PK, Morlacchi P, Knight JM, et al. Targeting the Src homology 2
production. Cytokine 2015;75:14–24. (SH2) domain of signal transducer and activator of transcription 6
26. Cajaiba MM, Borralho P, Reyes-Mugica M. The potentially lethal nature (STAT6) with cell-permeable, phosphatase-stable phosphopeptide mimics
of bronchial casts: plastic bronchitis. Int J Surg Pathol 2008;16:230–2. potently inhibits Tyr641 phosphorylation and transcriptional activity. J
27. Molfino NA, Nannini LJ, Martelli AN, et al. Respiratory arrest in Med Chem 2015;58:8970–84.
near-fatal asthma. N Engl J Med 1991;324:285–8.
28. Tomankova T, Kriegova E, Liu M. Chemokine receptors and their
therapeutic opportunities in diseased lung: far beyond leukocyte
trafficking. Am J Physiol Lung Cell Mol Physiol 2015;308:L603–18.